Treatment With Eribulin Mesylate in Metastatic Breast Cancer

3 विचारों
administrator
administrator
07/03/23

In this segment, panelists explore the cytotoxic agent eribulin mesylate, which has been the focus of several recent clinical trials. In all, despite a growing focus on targeted therapies, cytotoxics remain an important class of drugs in the treatment of patients with metastatic breast cancer.

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

  • श्रेणी

और दिखाओ

0 टिप्पणियाँ इसके अनुसार क्रमबद्ध करें

कोई टिप्पणी नहीं मिली

फेसबुक टिप्पणियाँ

अगला